388 related articles for article (PubMed ID: 33076918)
1. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.
Xu Y; Liu H; Song L
J Nanobiotechnology; 2020 Oct; 18(1):145. PubMed ID: 33076918
[TBL] [Abstract][Full Text] [Related]
2. Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.
Amore E; Ferraro M; Manca ML; Gjomarkaj M; Giammona G; Pace E; Bondì ML
Nanomedicine (Lond); 2017 Oct; 12(19):2287-2302. PubMed ID: 28868971
[TBL] [Abstract][Full Text] [Related]
3. Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: An emerging need for novel drug delivery systems.
Dua K; Malyla V; Singhvi G; Wadhwa R; Krishna RV; Shukla SD; Shastri MD; Chellappan DK; Maurya PK; Satija S; Mehta M; Gulati M; Hansbro N; Collet T; Awasthi R; Gupta G; Hsu A; Hansbro PM
Chem Biol Interact; 2019 Feb; 299():168-178. PubMed ID: 30553721
[TBL] [Abstract][Full Text] [Related]
4. Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.
Passi M; Shahid S; Chockalingam S; Sundar IK; Packirisamy G
Int J Nanomedicine; 2020; 15():3803-3826. PubMed ID: 32547029
[TBL] [Abstract][Full Text] [Related]
5. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
6. Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.
Dua K; Bebawy M; Awasthi R; Tekade RK; Tekade M; Gupta G; De Jesus Andreoli Pinto T; Hansbro PM
Pharm Nanotechnol; 2017; 5(4):243-249. PubMed ID: 28786352
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system.
Yoo NY; Youn YS; Oh NM; Oh KT; Lee DK; Cha KH; Oh YT; Lee ES
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):419-24. PubMed ID: 21820282
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress in COPD.
Kirkham PA; Barnes PJ
Chest; 2013 Jul; 144(1):266-273. PubMed ID: 23880677
[TBL] [Abstract][Full Text] [Related]
9. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets.
Rahman I
Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):291-315. PubMed ID: 14561194
[TBL] [Abstract][Full Text] [Related]
12. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.
De Rubis G; Paudel KR; Corrie L; Mehndiratta S; Patel VK; Kumbhar PS; Manjappa AS; Disouza J; Patravale V; Gupta G; Manandhar B; Rajput R; Robinson AK; Reyes RJ; Chakraborty A; Chellappan DK; Singh SK; Oliver BGG; Hansbro PM; Dua K
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2793-2833. PubMed ID: 37991539
[TBL] [Abstract][Full Text] [Related]
13. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
Brassington K; Selemidis S; Bozinovski S; Vlahos R
Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant therapeutic advances in COPD.
Rahman I
Ther Adv Respir Dis; 2008 Dec; 2(6):351-74. PubMed ID: 19124382
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant therapeutic targets in COPD.
Rahman I; Kilty I
Curr Drug Targets; 2006 Jun; 7(6):707-20. PubMed ID: 16787173
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
17. Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study.
Singh B; Ghosh N; Saha D; Sarkar S; Bhattacharyya P; Chaudhury K
Pulm Pharmacol Ther; 2019 Oct; 58():101831. PubMed ID: 31349003
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.
Dailah HG
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080309
[TBL] [Abstract][Full Text] [Related]
19. siRNA delivery to macrophages using aspherical, nanostructured microparticles as delivery system for pulmonary administration.
Fischer T; Tschernig T; Drews F; Brix K; Meier C; Simon M; Kautenburger R; Schneider M
Eur J Pharm Biopharm; 2021 Jan; 158():284-293. PubMed ID: 33285246
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Resveratrol on Inflammation and Oxidative Stress in a Rat Model of Chronic Obstructive Pulmonary Disease.
Wang XL; Li T; Li JH; Miao SY; Xiao XZ
Molecules; 2017 Sep; 22(9):. PubMed ID: 28895883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
